Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Payables (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Payables data on record, last reported at $525.5 million in Q1 2024.

  • For Q1 2024, Payables rose 27.68% year-over-year to $525.5 million; the TTM value through Mar 2024 reached $525.5 million, up 27.68%, while the annual FY2025 figure was $445.0 million, 15.59% down from the prior year.
  • Payables reached $525.5 million in Q1 2024 per RDY's latest filing, up from $411.6 million in the prior quarter.
  • Across five years, Payables topped out at $700.2 million in Q1 2022 and bottomed at $411.6 million in Q1 2023.
  • Average Payables over 5 years is $547.4 million, with a median of $525.5 million recorded in 2024.
  • Peak YoY movement for Payables: soared 40.72% in 2021, then crashed 41.22% in 2023.
  • A 5-year view of Payables shows it stood at $456.9 million in 2020, then surged by 40.72% to $643.0 million in 2021, then rose by 8.91% to $700.2 million in 2022, then plummeted by 41.22% to $411.6 million in 2023, then increased by 27.68% to $525.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Payables were $525.5 million in Q1 2024, $411.6 million in Q1 2023, and $700.2 million in Q1 2022.